The National Comprehensive Cancer Network (NCCN) currently recommends stratifying patients with NSCLC for immunotherapy based on PD-L1 expression, determined through tumor proportion score (TPS) via immunohistochemical (IHC) analysis on pathological samples [7]. This evidence concerns the gene CD274 and neoplasm.